Sarepta Therapeutics Income Statement (2010-2026) | SRPT

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	164.09M	22.50M	178.72M	188.80M	211.24M	230.27M	866.26M	231.50M	261.24M	309.32M	1,078.13M	413.46M	362.93M	467.17M	658.41M	133.33M	611.09M	399.36M	442.93M	730.80M
Cost of Revenue (Quarter)	19.52M	23.44M	31.74M	31.44M	37.80M	39.95M	30.80M	35.02M	34.12M	37.03M	44.18M	50.56M	44.55M	91.69M	132.30M	137.56M	152.56M	150.78M	398.71M	108.77M
Gross Profit (Quarter)	144.57M	-0.95M	146.98M	157.36M	173.44M	190.32M	835.46M	196.48M	227.11M	272.30M	1,033.95M	362.90M	318.39M	375.48M	526.11M	-4.23M	458.53M	248.58M	44.23M	622.03M
Operating items
Amortization - Intangibles (Quarter)	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.18M	0.44M	0.76M	0.60M	0.60M	0.60M	0.60M	0.60M	0.67M	0.68M	0.68M	0.69M
Research & Development (Quarter)	239.62M	139.12M	197.30M	194.25M	252.33M	216.71M	213.80M	245.68M	241.89M	194.30M	195.52M	200.40M	179.69M	224.48M	199.95M	773.45M	204.39M	218.89M	325.34M	153.96M
Selling, General & Administrative (Quarter)	72.35M	61.13M	78.06M	71.84M	154.32M	104.79M	120.48M	110.71M	118.56M	120.89M	131.70M	127.00M	138.80M	128.20M	163.87M	133.63M	137.90M	91.89M	128.30M	108.95M
Restructuring Costs (Quarter)																		40.50M	1.50M
Other Operating Expenses (Quarter)	102.00M			31.62M				35.20M	102.00M			51.16M				138.16M	153.22M	151.46M	399.38M	109.46M
Operating Expenses (Quarter)	331.66M	223.86M	307.27M	297.71M	444.62M	361.62M	365.26M	391.59M	394.76M	352.66M	372.16M	378.56M	363.63M	444.98M	496.73M	1,045.24M	495.51M	502.75M	854.52M	372.37M
Operating Income (Quarter)	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M	358.43M
EBIT (Quarter)	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M	358.43M
Non-operating items
Interest & Investment Income (Quarter)	0.05M	0.15M	0.38M	0.17M	2.41M	4.78M	1.54M	1.25M	-0.64M	0.42M	35.23M	-1.61M	-0.34M	3.27M			-0.09M	0.27M
Other Non Operating Income (Quarter)	-0.41M		-60.58M	-17.27M	-16.96M	98.50M	5.53M	387.30M				6.54M	14.28M		-32.63M	-83.13M	38.06M	138.60M	-157.91M	-15.26M
Non Operating Income (Quarter)	85.81M	-13.45M	-16.08M	-17.27M	-16.96M	-125.06M	-119.91M	-374.62M	118.93M	-12.33M	15.75M	6.54M	14.28M	11.81M	10.06M	-83.13M	38.06M	-90.66M	133.29M	-15.26M
Net income details
EBT (Quarter)	-81.76M	-47.91M	-121.89M	-104.15M	-228.09M	-256.42M	337.27M	-512.71M	-14.59M	-33.17M	40.37M	41.45M	13.58M	34.01M	171.74M	-383.52M	153.64M	-194.05M	-278.30M	343.17M
Tax Provisions (Quarter)	-0.35M	0.24M	0.40M	0.88M	3.39M	1.32M	7.94M	4.00M	9.36M	7.76M	-5.12M	5.33M	7.12M	0.40M	12.94M	64.00M	-43.30M	-14.10M	4.58M	12.20M
Profit After Tax (Quarter)	-81.41M	-48.14M	-121.98M	-105.03M	-231.48M	-257.74M	-106.06M	-516.75M	-23.94M	-40.94M	45.66M	36.12M	6.46M	33.61M	159.05M	-447.51M	196.89M	-50.57M	-412.23M	350.86M
Income from Continuing Operations (Quarter)	-81.41M	-48.14M	-122.29M	-105.03M	-231.48M	-257.74M	329.33M	-516.71M	-23.94M	-40.94M	45.49M	36.12M	6.46M	33.61M	158.80M	-447.52M	196.94M	-179.95M	-282.88M	330.97M
Consolidated Net Income (Quarter)	-81.41M	-48.14M	-122.29M	-105.03M	-231.48M	-257.74M	329.33M	-516.71M	-23.94M	-40.94M	45.49M	36.12M	6.46M	33.61M	158.80M	-447.52M	196.94M	-179.95M	-282.88M	330.97M
Income towards Parent Company (Quarter)	-81.41M	-48.14M	-122.29M	-105.03M	-231.48M	-257.74M	329.33M	-516.75M	-23.94M	-40.94M	45.49M	36.55M	6.80M	33.61M	158.80M	-447.52M	196.94M	-179.95M	-282.88M	330.97M
Net Income towards Common Stockholders (Quarter)	-81.41M	-48.14M	-122.29M	-105.03M	-231.48M	-257.74M	329.33M	-516.75M	-23.94M	-40.94M	45.49M	36.55M	6.80M	33.61M	158.80M	-447.52M	196.94M	-179.95M	-282.88M	330.97M
Additional items
EPS (Basic) (Quarter)	-1.02	-602.70	-1.50	-0.00M	-20.49	-23.01	3.76	-5.86	-0.27	-0.46	0.49	0.39	0.07	0.35	1.67	-4.60	2.01	-1.80	-2.83	3.15
EPS (Diluted) (Quarter)	-1.02	-602.70	-1.50	-0.00M	-0.00M	-0.00M	3.76	-5.86	-0.27	-0.46	0.49	0.37	0.07	0.33	1.47	-4.60	1.85	-1.80	-2.83	2.71
Shares Outstanding (Quarter)	79.75M	0.08M	81.26M	0.09M	11.30M	11.20M	87.56M	88.19M	88.74M	88.89M	92.40M	93.99M	94.62M	95.39M	95.08M	97.36M	98.00M	100.24M	100.12M	104.99M
Shares Outstanding (Diluted) (Quarter)	79.75M	0.08M	81.26M	0.09M	0.09M	0.09M	87.56M	88.19M	88.74M	88.89M	92.40M	99.11M	99.14M	100.45M	107.88M	97.36M	106.62M	100.24M	100.12M	121.92M
Shares Outstanding (Entity) (Quarter)	79.83M	0.08M	87.13M	0.09M	11.30M	11.20M	87.95M	93.14M	93.27M	93.54M	93.73M	94.49M	95.28M	95.49M	96.90M	98.25M	98.36M	105.42M	105.62M	106.23M
EBITDA (Quarter)	-167.57M	-34.46M	-105.81M	-86.88M	-211.13M	-131.35M	-106.83M	-138.09M	-133.52M	-20.84M	24.62M	34.91M	-0.70M	22.20M	161.68M	-300.39M	115.58M	-103.39M	-411.58M	358.43M
Interest Expenses (Quarter)	16.18M	20.65M	11.16M	15.80M	16.96M	14.74M	-94.52M	7.02M	5.22M	5.23M	-38.79M	7.19M	4.83M	897.00M	19.31M	989.60M	1,131.80M	1,100.50M	-40.04M	1,034.70M
Tax Rate (Quarter)	0.43%	-0.49%	-0.33%	-0.84%	-1.49%	-0.51%	2.35%	-0.78%	-64.14%	-23.40%	-12.68%	12.86%	52.42%	1.16%	7.54%	-16.69%	-28.18%	7.27%	-1.65%	3.56%

Research Tools

Developers

Sarepta Therapeutics Income Statement (2010-2026) | SRPT

Research Tools

Developers

Sarepta Therapeutics Income Statement (2010-2026) | SRPT

Create an account

Sign In

Reset Password